Drug intelligence / Profile preview

nSf-NiVac

Development stage: Preclinical
Lead developer: Sferogen
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

nSf-NiVac is a monovalent protein nanoparticle vaccine candidate developed by Sferogen for the prevention of Nipah virus infection. Utilizing Sferogen's proprietary nanoSFERIC platform, the vaccine is engineered to present Nipah virus antigens in a highly organized nanoparticle structure, which is designed to elicit a robust and structured adaptive immune response. The candidate is currently in the preclinical stage of development and is positioned as a key asset in Sferogen's pipeline for pandemic preparedness against high-consequence zoonotic pathogens.

Other names: nanoSFERIC/Nipah virusnSf-NiVac (monovalent)nanoSFERIC Nipah virus vaccine

Targets

NiV-G (Nipah virus attachment glycoprotein)

Beyond the preview

Go deeper on nSf-NiVac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nSf-NiVac.

Explore the full profile